key: cord-0742149-i24pclju
authors: Sohrabi, Yahya; Reineceke, Holger; Joosten, Leo A.B.; Netea, Mihai G.
title: Deadly COVID-19 Among the Elderly: Innate Immune Memory Helping those Most in Need
date: 2021-02-24
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.02.004
sha: c1db66fe883e88b95643ec5b9952e64c6ce26b3e
doc_id: 742149
cord_uid: i24pclju

Age is a key risk factor associated with the severity of symptoms caused by SARS-Co-V2 and there is an urgent need to reduce COVID-19 morbidity and mortality in elderly individuals. We discuss evidence suggesting that trained immunity elicited by BCG vaccination may improve immune responses and can serve as a strategy to combat COVID-19 in this population.

We discuss evidence suggesting that trained immunity elicited by BCG vaccination may improve 23 immune responses and can serve as a strategy to combat COVID-19 in this population. CoV-2). The disease spreads very quickly and became a pandemic short after it emerged China in 52

December 2019. Depending on the patients' health conditions and age, COVID-19 clinical symptoms can 53 range from an asymptomatic or mild disease to a very severe form. Pre-existing underlying health 54 conditions such as diabetes, atherosclerosis, hypertension, cancer, immunocompromised states, chronic 55 kidney disease and overweight/obesity substantially increase COVID-19 mortality and morbidity 1 . In 56 addition, COVID-19 severity drastically increases with advancing age 2,3 . In patients with severe disease, 57 COVID-19 induces a complex dysregulation of both innate and adaptive immune responses, that 58 sometimes result in a combination of inappropriate systemic inflammation (leading to pulmonary 59 edema and respiratory insufficiency), as well as defects in specific components of the immune responses 60 (e.g. interferon pathway defects, lymphopenia), contributing to disease severity 1, 4 . Older people have a 61 higher chance of developing a systemic inflammation when encountering COVID-19 4 . 62 63

Aging is one of the main risk factors for increased susceptibility to many infectious diseases. 65

Systematic analysis of more than 140 databases on 19 viral and 13 bacterial diseases demonstrated that 66 severity increases with age and clinical symptoms markedly worsen in older ages 5,6 . Although the 67 COVID-19 pandemic affects people across all ages, children and young adults 10-19 years old show very 68 mild or no symptoms. In contrast, the elderly are the most vulnerable group to the disease and are often 69 hospitalized and require intensive care unit support 3,6 . Subsequently, the mortality rate among this age 70 group is significantly higher than among younger or middle-aged groups. Individuals under 20 years of 71 age are almost half as susceptible to COVID-19 as those over 20. Clinical symptoms increased 72 dramatically to 57-82% in adults aged over 65-70 years 6 . 73

Increased susceptibility to disease is a complex and multifactorial process. Physiologic 74 alterations affect many organs such as the skin, epithelium and mucosal tissue. In addition, poor disease 75 outcome is closely associated with the immune system weakening during aging 2 (Figure 1 ). Age-76 associated changes in both lymphocytes functions and proportions have been linked to chronic diseases. 77 Lymphoid tissues deteriorate with rising age and fail to support lymphocyte hemostasis, which result in 78 less T and B cells and finally less robust cellular and humoral immune responses. Evidences also shows 79 that aging causes hematopoiesis shift toward myelopoiesis from lymphoid to myeloid progenitors. This 80 may contribute to lower lymphoid cell numbers and a higher number of myeloid derived cells such as 81 monocytes/macrophages 2,5 . With aging, the frequency of naïve CD4+ or CD8+ T cells decreases but the number of memory CD4+ or CD8+ T cells increases or remains the same 2,5,7 . Moreover, the normal 83 function of TCR and cytokine production by T cells is also impaired 7 . All these changes in adaptive 84 immunity agents lead to a decline in their ability to build a proper immune response against new 85 antigens, and thus poor response to vaccination. This is referred to as immunosenescence (reduced 86 proliferation) and exhaustion (reduced inflammatory mediators such as cytokines production) 3,7 . 87 Exhausted T cells continuously produce small amounts of proinflammatory cytokines such as IFNγ and 88

TNFα, which induces low grade inflammation in bodies of older age 3 . 89 These neutralizing antibodies were associated with a protective response against COVID-19 and were 99 tested as vaccine candidates in non-human primates 2 . Conversely, strong SARS-CoV-2-specific CD4+ or 100 CD8+ T cell responses were associated with protection against the disease and milder symptoms in the 101 acute phase. With aging, frequencies of naïve CD8+ and CD4+ T cells are dramatically reduced and their 102 responses against diseases including COVID-19 significantly altered 2 . In order to mount a well-defined 103 immune response against a pathogen, the immune system uses highly coordinated processes involving 104 many cells and mediators. Moderbacher and her colleagues demonstrated that the alteration in 105 coordination of the immune system in older people is a reason why they cannot compete against the 106 novel coronavirus 2 . Impairment or loss of coordination of the CD4+ and CD8+ T cell responses and lack 107 of proper coordination between the CD4+ T cell and antibody responses lead to a severe form of COVID-108 19 in the elderly. Interestingly, there was a strong association between low frequencies of naïve CD8+ 109 and CD4+ T cells, severity of COVID-19, and age. On the other hand, acute cases which had high IFNγ -110 producing CD8+ T cells exhibited mild symptoms 2 . Intriguingly, pairwise analysis revealed a positive 111 association between disease severity, antigen specific antibodies and CD4+ and CD8+ T cells responses, 112 but neutralizing antibodies alone were not a factor to reduce disease symptoms. This suggests that an 113 J o u r n a l P r e -p r o o f efficient coordination between all three arms of the adaptive immunity is needed for protection against 114 COVID-19, which is almost lacking in the elderly 2 . 115 116 Age associated defects in the innate immune system 117 Innate immunity is the first line of defense that responds immediately upon encountering a 118 threat. It also plays a crucial role in initiating an effective adaptive immunity. The innate immune system 119 is affected by age to a lesser degree. Adaptive immune cells respond to inflammatory stimuli in an 120 antigen specific manner, whereas innate immune cells provide nonspecific defense against invading Vaccination is the most effective way to prevent infectious diseases. However, in general 179 vaccines are less effective in older people. For example, the influenza vaccine efficiency is reduced to 180 about 20-60% in older population 6-8 . It is therefore an emerging task to protect the most vulnerable 181 against the diseases. Development of an effective vaccine against COVID-19 has resulted in exciting 182 news regarding several potential candidates with a good effectiveness and safety profile, at least in 183 young individuals, but it is an additional concern to increase efficacy of the potential vaccine in the 184 elderly. Immune system and vaccine effectiveness in the elderly can be boosted by several ways. 185

Changing the administration rout or the use of adjuvants can increase the efficiency of vaccines 7 . 186

Another strategy is using a trained immunity approach to boost Considering the impairment of the elderly immune system, these data suggest that BCG is able 230 to recover both innate immune system and the T cell immune responses and significantly influences the 231 level of immune responsiveness. BCG is able to induce adaptive and innate immune responses and have 232 a beneficial effect on coordination of both systems, thus can result in more efficient and effective 233 protection against COVID-19 in the older ages. Moreover, the prevalence of cancer diseases such as non-234 muscle-invasive bladder cancer and melanoma are significantly higher in older people and BCG 235 administration against COVID-19 might have protective effects against those diseases, which is beyond 236 its intended scope. It is important to study whether BCG administration can also restore hematopoietic 237 progenitor cell functions and frequency in aged humans. It has been shown that trained immune 238 memory can also be induced in non-immune cells, such as stromal and epithelial cells 1 

are the first host cells to be infected by SARS-CoV-2 that is why they are particularly important target 240 cells for the induction of innate immune memory. 241

In conclusion, BCG-induced innate immune memory can improve antiviral-host defense in older 242 people. Several epidemiological and proof-of-principle studies have shown that BCG vaccination prior to 243 other vaccines boosts the efficiency 15 . This suggests that building a pre-existing immunological memory 244 not only could be a strategy to protect the elderly against new infection, but also be a tool to strength 245 their immune system capabilities and increase the efficacy of vaccines. It is very important to consider 246 that currently, BCG is used as a routine neonatal vaccination policy in 152 countries and also is used as 247 an immunotherapy for non-muscle-invasive bladder cancer and melanoma worldwide 1, 10 

Trained immunity as a novel approach against COVID-19 with a focus on 270

Bacillus Calmette-Guerin vaccine: mechanisms, challenges and perspectives

Antigen-Specific Adaptive Immunity to 274 SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

COVID-19 is an emergent 278 disease of aging

Immune 280 response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered 281 by SARS-CoV-2

Age-Related Decline in Primary CD8(+) T Cell Responses Is 284 Associated with the Development of Senescence in Virtual Memory CD8(+) T Cells

Systematic analysis of infectious disease outcomes by age 287 shows lowest severity in school-age children

Fighting against a protean enemy: immunosenescence, vaccines, and 290 healthy aging

Overcoming immune 292 dysfunction in the elderly: trained immunity as a novel approach

Reduced development 295 of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating 296 potential therapeutics

BCG vaccine protection from severe 299 coronavirus disease 2019 (COVID-19)

Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly

BCG Vaccination in Humans Elicits Trained 307 Immunity via the Hematopoietic Progenitor Compartment

BCG-induced trained immunity in NK cells: Role for non-311 specific protection to infection